FindTrial
Sign In

Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia

Critical Role of MicroRNA-34a and MicroRNA-194 in Acute Myeloid Leukemia With CEBPA Mutations

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01057199
Enrollment
6
Registered
2010-01-27
Start date
2010-01-31
Completion date
2010-06-30
Last updated
2015-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

adult acute myeloid leukemia, childhood acute myeloid leukemia/other myeloid malignancies

Brief summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at biomarkers in cell samples from patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: * To determine the significance of regulation of microRNA-34a and microRNA-194 by C/EBPα during granulopoiesis in patients with acute myeloid leukemia with CEBPA mutations. * To determine whether overexpression of micro RNA-34a and microRNA-194 in myeloid progenitors with C/EBPα mutations leads to granulocytic differentiation. * To examine how microRNA-34a and microRNA-194 downregulate E2F3 during granulopoiesis. * To determine the role of microRNA-34a and microRNA-194 in myeloid cell proliferation. OUTLINE: Cryopreserved cell samples are collected for laboratory analysis, including mutation analysis, gene expression analysis, RNA analysis, and fluorescence-activated cell sorting (FACS) analysis.

Interventions

GENETICRNA analysis
GENETICgene expression analysis
GENETICmutation analysis
GENETICprotein expression analysis
OTHERfluorescence activated cell sorting
OTHERlaboratory biomarker analysis

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Children's Oncology Group
Lead SponsorNETWORK

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of acute myeloid leukemia with CEBPA mutations PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

MeasureTime frame
Significance of regulation of microRNA-34a and microRNA-194 by C/EBPα during granulopoiesis—
Relationship between overexpression of microRNA-34a and microRNA-194 in myeloid progenitors with C/EBPα mutations and granulocytic differentiation—
Downregulation of E2F3 by microRNA-34a and microRNA-194 during granulopoiesis—
Role of microRNA-34a and microRNA-194 in myeloid cell proliferation—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026